Inhibition of insulin degradation by insulin-like growth factors I and II in human hepatoma (HepG2) cells.
IGF-I infused at pharmacological doses in healthy men markedly decreases C-peptide levels, whereas insulin levels remain within the normal range. One possible explanation is decreased insulin removal. As the liver is the major site of insulin degradation, we studied insulin degradation by HepG2 cells in the presence of IGF. We found that IGF-I at a concentration of 130 nmol/l inhibits insulin degradation by HepG2 cells when the initial insulin concentration is 0.34 nmol/l. The effect of IGF-I on insulin degradation is dose-dependent and the rate of insulin degradation is dependent on the insulin concentration. IGF-II is 6 to 10 times more potent than IGF-I in inhibiting 125I-insulin binding to HepG2 cells and in protecting insulin from being degraded. Thus, IGF-I and IGF-II inhibit insulin degradation most likely by competing for binding at insulin binding sites of liver cells.
Keller
S
S
Department of Medicine, University Hospital Zurich, Switzerland.
Schmid
C
C
Zapf
J
J
Froesch
E R
ER
D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D002460:Cell Line; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000378:metabolism*; D011972:Receptor, Insulin / Q000187:drug effects; D013002:Somatomedins / Q000494:pharmacology*
D007328:Insulin; D013002:Somatomedins; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D011972:Receptor, Insulin